Table 1. Characteristics of the study population according to molecular subgroups.
| NSMP (n = 218) | POLE EDM (n = 37) | MMR-D (n = 191) | p53 abn (n = 69) | P | |
|---|---|---|---|---|---|
| Age (years) [median (interquartile range)] | 66 (60−73) | 59 (53−68) | 70 (61−77) | 72 (66−78) | <0.0005 |
| Age >65 years | 116 (53.2%) | 11 (29.7%) | 121 (63.4%) | 52 (75.4%) | <0.0005 |
| Body mass index (kg/m2) [median (interquartile range)] | 28.5 (24.3−33.2) | 25.1 (23.0−28.3) | 27.1 (23.3−32.7) | 27.3 (24.4−30.5) | 0.023 |
| Overweight/obese | 157 (72.0%) | 21 (56.8%) | 118 (61.8%) | 45 (65.2%) | 0.091 |
| World Health Organization class III obesity | 14 (6.4%) | 1 (2.7%) | 7 (3.7%) | 3 (4.3%) | 0.541 |
| Type 2 diabetes | 40 (18.3%) | 4 (10.8%) | 37 (19.4%) | 13 (18.8%) | 0.671 |
| Pelvic lymphadenectomy | 129 (59.2%) | 23 (62.2%) | 106 (55.5%) | 32 (46.4%) | 0.255 |
| Pelvic-aortic lymphadenectomy | 19 (8.7%) | 5 (13.5%) | 34 (17.8%) | 22 (31.9%) | <0.0005 |
| Stage | <0.0005 | ||||
| IA | 123 (56.4%) | 28 (75.7%) | 84 (44.0%) | 22 (31.9%) | |
| IB | 42 (19.3%) | 6 (16.2%) | 44 (23.0%) | 18 (26.1%) | |
| II | 23 (10.6%) | 2 (5.4%) | 19 (9.9%) | 1 (1.4%) | |
| IIIA | 9 (4.1%) | 1 (2.7%) | 13 (6.8%) | 5 (7.2%) | |
| IIIB | 1 (0.5%) | 0 (0%) | 2 (1.0%) | 1 (1.4%) | |
| IIIC1 | 13 (6.0%) | 0 (0%) | 18 (9.4%) | 3 (4.3%) | |
| IIIC2 | 1 (0.5%) | 0 (0%) | 7 (3.7%) | 9 (13.0%) | |
| IVA | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | |
| IVB | 6 (2.8%) | 0 (0%) | 4 (2.1%) | 10 (14.5%) | |
| Histology | <0.0005 | ||||
| Endometrioid carcinoma | 206 (94.5%) | 34 (91.9%) | 174 (91.1%) | 36 (52.2%) | |
| Clear cell carcinoma | 5 (2.3%) | 2 (5.4%) | 5 (2.6%) | 13 (18.8%) | |
| Serous carcinoma | 2 (0.9%) | 1 (2.7%) | 3 (1.6%) | 11 (15.9%) | |
| Carcinosarcoma | 2 (0.9%) | 0 (0%) | 3 (1.6%) | 7 (10.1%) | |
| Undifferentiated carcinoma | 3 (1.4%) | 0 (0%) | 6 (3.1%) | 2 (2.9%) | |
| Grade (For endometrioid only; n = 450) | <0.0005 | ||||
| 1 | 141 (68.4%) | 21 (61.8%) | 79 (45.4%) | 5 (13.9%) | |
| 2 | 52 (25.2%) | 8 (23.5%) | 54 (31.0%) | 15 (41.7%) | |
| 3 | 13 (6.3%) | 5 (14.7%) | 41 (23.6%) | 16 (44.4%) | |
| Adjuvant therapy | <0.0005 | ||||
| None | 33 (15.1%) | 6 (16.2%) | 20 (10.5%) | 7 (10.1%) | |
| Vaginal brachytherapy | 116 (53.2%) | 22 (59.5%) | 83 (43.5%) | 18 (26.1%) | |
| Pelvic radiotherapy | 28 (12.8%) | 6 (16.2%) | 35 (18.3%) | 12 (17.4%) | |
| Chemotherapy | 7 (3.2%) | 0 (0%) | 8 (4.2%) | 7 (10.1%) | |
| Chemotherapy and vaginal brachytherapy | 10 (4.6%) | 0 (0%) | 10 (5.2%) | 11 (15.9%) | |
| Chemotherapy and pelvic radiotherapy | 24 (11.0%) | 3 (8.1%) | 35 (18.3%) | 14 (20.3%) |
Abbreviations: MMR-D, mismatch repair deficient; NSMP, no specific molecular profile; POLE EDM, polymerase-ϵ exonuclease domain mutation; p53 abn, p53 abnormal.